Variants of the CASP9 gene as candidate markers for primary response to anti-TNF therapy in Crohn's disease patients.

ABSTRACT: Anti-tumor necrosis factor (TNF) therapy is used to induce and maintain remission in Crohn's disease (CD) patients. However, primary non-responders to initial treatment constitute 20-40% of cases. The causes of this phenomenon are still unknown. We aim to investigate the impact of the caspase 9 (CASP9) gene variants on the variable reactions of CD patients to anti-TNF therapy. The study group included 196 diagnosed and clinically characterized CD Polish patients following anti-TNF therapy. The sequence of the CASP9 gene was analyzed using next-generation and Sanger sequencing and was analyzed with the response to biological treatment. Using the RT-qPCR analysis, we estimated the CASP9 gene mRNA level in colon biopsies material from inflamed and non-inflamed tissue (21 CD patients: 14 respo

SUBMITTER: Lykowska-Szuber L 

PROVIDER: S-EPMC10632275 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature